LongevityIn Clinical Trials

NAD+ Precursors (NMN)

Oral, Intravenous, Sublingual

Overview

Nicotinamide mononucleotide (NMN) is a direct biosynthetic precursor to nicotinamide adenine dinucleotide (NAD+), a coenzyme essential for cellular metabolism, DNA repair (via sirtuins and PARPs), and circadian rhythm regulation.

Mechanism of Action

NAD+ levels decline with age, and NMN supplementation restores tissue NAD+ levels, activating SIRT1-mediated pathways that regulate mitochondrial biogenesis and oxidative stress resistance..

Research Summary & Key Findings

Long-term NMN administration improved age-related physiological decline in mice including insulin sensitivity, lipid profiles, and physical activity (Mills et al., Cell Metabolism, 2016). Human clinical trial showed increased NAD+ metabolites and improved muscle insulin sensitivity in prediabetic women (Yoshino et al., Science, 2021). Multiple Phase 2 trials ongoing.

Clinical Status

In Clinical Trials

NAD+ Precursors (NMN) is currently undergoing clinical trials. It is not yet FDA-approved and is available only through clinical research settings or investigational protocols.

Administration Routes

OralIntravenousSublingual

Related Peptides in Longevity

Find a Provider

Find a verified provider who offers NAD+ Precursors (NMN) therapy in your area.

Browse Provider Map

Find a Pharmacy

Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply NAD+ Precursors (NMN).

Pharmacy Directory

Join the Association

Access exclusive peptide protocols, provider resources, and community support.

List Your Practice

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol.